Precede Biosciences

Precede Biosciences has developed a first-in-class liquid biopsy platform to provide insights into disease-defining biology. Precede's platform uses machine learning and molecular biology to create profiles of circulating chromatin and the DNA methylome. This gives users access to about 20,000 gene promoters, one million gene enhancers, and 50,000 CpG islands - thereby gaining insights about individual genes and their pathways. Precede's goal is to improve drug development success rates and to provide patients with rapid, minimally invasive diagnoses and therapies.